Tumors promote their own growth and evade immunosurveillance. The ability of malignant cells to establish immunosuppressive conditions plays a major role in tumor progression by interfering with immunological control mechanisms. The precise nature of tumor-associated immunosuppression varies with cancer type, is biologically complex, and often involves perturbation of both innate and adaptive mechanisms that would otherwise eradicate malignant lesions.[@R1]

While the use of pathogenic microorganisms in cancer immunotherapy is not novel, protozoan parasites are relatively unexplored in this context. *Toxoplasma gondii* is an obligate intracellular protozoan parasite that actively invades host cells. *Toxoplasma* cells preferentially contact and invade myeloid cells including dendritic cells and monocytes/macrophages,[@R2] which are frequently involved in tumor-elicited immunosuppression. By invading myeloid cells, *T. gondii* gains direct access to the control of innate immune cells, generally resulting in the elicitation of potent T~H~1 immune responses.[@R3] During invasion, *Toxoplasma* cells secrete a repertoire of specialized molecules that function to seize control of the host cell from within.[@R3] The parasite also hijacks bystander cells as the molecules that it produces are injected into cells that are contacted but are not invaded.[@R4] For example, *T. gondii* injects the rhoptry (ROP)16 kinase into macrophages, suppressing the signal transducer and activator of transcription 3 (STAT)3-dependent production of interleukin-12 (IL-12), and upregulating arginase 1 upon the activation of STAT6.[@R5] *Toxoplasma* cells also secrete ROP18, a kinase that protects the vacuole housing intracellular parasites from innate immune attack mechanisms mediated by a family of interferon γ (IFNγ)-activated GTPases.[@R6] Additional molecules secreted by *T. gondii* play significant roles in manipulating host cells and immune responses.[@R3]

A safe, live-attenuated, non-replicating variant of *T. gondii* was created as an uracil auxotroph (*cps*) strain.[@R7] While uracil auxotrophs normally invade mammalian cells, they do not replicate in the absence of uracil, thus exhibiting an exquisite degree of attenuation of virulence in both normal and severely immunodeficient mice.[@R7]^,^[@R8] In contrast to many prokaryotic microbes, the eukaryotic *T. gondii* does not harbor any significant toxin or otherwise toxic molecule. We therefore reasoned that strongly polarized T~H~1 host responses driven *T. gondii-*secreted factors and the manipulation of innate immune cells by means of the *cps* strain would stimulate responses in the tumor microenvironment that could break tumor-associated immunosuppression.

Immature CD11c^+^ dendritic cells accumulate in high amounts within solid epithelial tumors including ovarian carcinomas, and deliver signals that create a highly immunosuppressive microenvironment.[@R9] Treatment of established aggressive vascular endothelial growth factor (VEGF)-expressing ID8 ovarian tumors with the *cps* strain resulted in tumor regression and improved the survival of tumor-bearing mice.[@R9] Of note, the administration of the *cps* strain was equally effective in naïve mice as well as in mice that were immune to *Toxoplasma*. The immunotherapeutic effects of *cps* cells was completely dependent on IL-12, but not on Toll-like receptor (TLR) adaptor myeloid differentiation 88 (MYD88).[@R9] In the tumor microenvironment as well as ex vivo, the *cps* strain preferentially invaded CD45^+^CD11c^+^ cells and both *cps*-infected and *cps*-contacted cells exhibited increased expression levels of the co-stimulatory molecules CD80 and CD86. The treatment of ovarian carcinomas with the *cps* strain rapidly reversed tumor-associated immunosuppression and stimulated the priming of CD8^+^ T-cell responses by antigen-presenting cells.[@R9] Tumor antigen-specific CD8^+^ (and granzyme B^+^) T cells were increased both in the spleen and in the tumor microenvironment upon the administration of the *cps* strain,[@R9] and adoptive transfer experiments demonstrated that T cells from treated mice potently suppressed the development of ovarian carcinomas.[@R9] The *cps* strain also stimulated the recruitment of numerous cell types to neoplastic lesions and to the spleen. Of note, while the T~H~17^+^ cells were not increased by our immunotherapeutic approach, the percentage of intratumoral regulatory T cells (CD4^+^FOXP3^+^ T cells) was significantly decreased.

Along similar lines, the administration of the *cps* strain elicited the immune system-mediated regression of established B16F10 melanomas.[@R10] More than 90% of *cps*-treated mice survived B16F10 melanoma and most of these animals developed localized and/or systemic vitiligo, as indication of the recognition of melanocytes by the immune system. The therapeutic efficacy of *cps* cells required the participation of both natural killer (NK) cells and CD8^+^ T lymphocytes but not of CD4^+^ T cells. Moreover, also in this setting, the efficacy of *cps*-based immunotherapy was completely dependent on IL-12 and IFNγ. Living *cps* parasites were necessary for the elicitation of antitumor responses, suggesting a requirement for the active invasion of host cells by the parasite and their manipulation upon the secretion of effector molecules. Multiple cell types were invaded by *cps* parasites in the melanoma microenvironment, and various cell types were recruited to neoplastic lesions, tumor-draining lymph node, and the spleen.[@R10] The treatment increased the frequency of IFNγ-expressing CD8^+^ T cells specific for a melanoma-associated antigen, namely dopachrome tautomerase (DCT, also known as TRP2). The re-challenge of mice that survived melanoma upon the administration of the *cps* strain with living melanoma cells failed to support a second wave of oncogenesis, suggesting that *cps*-based immunotherapy generated significant memory responses.[@R10] Collectively, these results reveal that immunotherapeutic approaches based on a non-replicating variant of *T. gondii* can reverse tumor-associated immunosuppression and stimulate effective immune responses against solid tumors ([Fig. 1](#F1){ref-type="fig"}).

![**Figure 1.** Active invasion by *Toxoplasma gondii* reverses tumor-elicited immunosuppression and activates tumor-targeting immune responses. Immunosuppressive myeloid CD11c^+^ cells in the tumor microenvironment are preferentially invaded by the non-replicating *cps* strain of *T. gondii*. Invaded or contacted myeloid cells are activated to produce interleukin-12 (IL-12) and to express increased levels of the co-stimulatory molecules CD80 and CD86 on their surface. The *cps* strain induces the maturation of myeloid CD11c^+^ cells, leading to increased antigen-presentation and T-cell priming. Eventually this results in the expansion of activated natural killer (NK) cells and CD8^+^ T lymphocytes, which release interferon γ (IFNγ) into the tumor microenvironment. Cellular responses such as those mediated by NK cells and tumor-specific CD8^+^ T lymphocytes mediate the killing of cancer, hence causing tumor regression.](onci-2-e26296-g1){#F1}

A major advantage of *cps*-based immunotherapy is its versatility. The *cps* strain was originally developed as a self-adjuvant platform for stimulating potent T~H~1 immune responses to engineered CD8^+^ T-cell vaccines.[@R7] *T. gondii* uracil auxotrophs can be easily engineered with conventional genetic techniques to exacerbate vaccine-elicited immune responses, to express specific molecules (or exert selected functions) in the tumor microenvironment, or to selectively target particular cell types. These versatile biological features along with the inherent and potent immunotherapeutic potential of the *cps* platform itself open multiple avenues and a wide-range of potential applications. Exploiting the unique biology of the safe *Toxoplasma* uracil auxotroph vaccine platform is expected to drive the development of innovative cancer vaccines that are able to eradicate established lesions as well as prevent disease recurrence.
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